Oral MS Drug Remibrutinib Avoids Liver Toxicity Seen in Class
Adults with relapsing multiple sclerosis may want to discuss this oral candidate with their neurologist, since its relapse results trailed a rival.
Updated on Nov. 4, 2026 in Stroke

Novartis's oral BTK inhibitor remibrutinib, a candidate for relapsing multiple sclerosis, had detailed Phase III results from its REMODEL-1 and REMODEL-2 trials presented at the MSToronto2026 conference. The annualised relapse rates did not meet some investors' expectations, and FirstWord is now polling neurologists on how clinically significant the results are.
Why it matters
Multiple sclerosis treatment decisions depend on how strongly a drug reduces relapses and disability progression, so neurologists' appraisal of this candidate will shape how it is weighed against existing options. The candidate's safety profile also matters because several other drugs in the same class have faced partial clinical holds over liver-related drug injury.
The data come from two Phase III trials, REMODEL-1 and REMODEL-2, presented at MSToronto2026, with detailed results now public. Remibrutinib's relapse results fell short of some investor expectations and were numerically smaller than those reported for fenebrutinib in its own trials.
The players
Novartis
Novartis is a global pharmaceutical company with a major multiple sclerosis franchise and is developing remibrutinib as an oral BTK inhibitor candidate.
FirstWord Pharma
FirstWord Pharma is a pharmaceutical market intelligence company that conducts physician polling and analysis of drug development programmes.
The details
Remibrutinib is an oral BTK inhibitor, a class of drugs that blocks Bruton's tyrosine kinase, an enzyme involved in immune cell signalling that is thought to drive inflammation in multiple sclerosis. Unlike other BTK inhibitors in this class, remibrutinib has not shown the liver toxicity that has led to partial clinical holds for fenebrutinib, tolebrutinib, evobrutinib and orelabrutinib. FirstWord is asking neurologists how clinically significant the trial results are and how reductions in disability progression shape their overall judgement of the drug.
Timeline
Detailed REMODEL-1 and REMODEL-2 results were presented at MSToronto2026 in 2026.
FirstWord's article on the neurologist poll was published on 4 November 2026.
Poll results will be published soon for FirstWord Pharma PLUS subscribers.
Health Landscape
Remibrutinib sits within a crowded BTK inhibitor pipeline in which fenebrutinib, tolebrutinib, evobrutinib and orelabrutinib have all faced partial clinical holds for liver-induced drug injury. Its cleaner liver profile, combined with its more modest relapse reduction than fenebrutinib in the FENhance trials, places it as a candidate that could be used earlier in the multiple sclerosis disease course.
If you live with relapsing multiple sclerosis, this development is worth discussing with your neurologist, who can explain how a newer oral option might compare with your current treatment. The drug's cleaner liver safety profile relative to other BTK inhibitors is the kind of factor worth raising when weighing future treatment choices.
The takeaway
Remibrutinib's cleaner liver safety profile is a notable point in a class where several candidates have faced clinical holds. Anyone managing relapsing multiple sclerosis should bring questions about how emerging oral options compare with their current treatment to their neurologist.
What happens next
FirstWord has said poll results will be published soon for its Pharma PLUS subscribers, which will show how neurologists view the trial results.
Further reading
For broader context on neurological conditions and treatments, explore our Stroke coverage.
Source note: This article includes information reported by Firstwordpharma.


